Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02779738 · ClinicalTrials.gov registry record · Phase 1
A Study of Merestinib (LY2801653) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02779738 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants.
The verdict
NCT02779738, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of food on merestinib (standard meal and high-fat meal) compared to the fasted state. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In addition, the tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last approximately 28 days. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG Merestinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02779738
The ClinicalTrials.gov registry entry for NCT02779738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Merestinib is the first listed.
NCT02779738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02779738 about?
NCT02779738 is a clinical study titled "A Study of Merestinib (LY2801653) in Healthy Participants". The purpose of this study is to evaluate the effect of food on merestinib (standard meal and high-fat meal) compared to the fasted state. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In addition, the tolerability o...
What is the current status of trial NCT02779738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02779738?
The interventions under investigation include: Merestinib (DRUG).
Who is sponsoring clinical trial NCT02779738?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.